FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Notes forming part of the statement of Profit and loss for the year ended 31st March 2022

PARTICULARS		For the year ended	For the year ended
	Note	31st March, 2022	31st March, 2021
		Amount In ₹	Amount In ₹
ncome From Operations	2.01		
Income from Dialysis Unit	1 1	97,79,344	- 1,05,17,390
Income from Dialysis IPD			16,75,800
Income from Pathology (Care parth)	1 1	93,86,698	-
Income from OT	1 1	1,20,000	
Income from Holter	1 1	10,400	4. 15
Income from ECG		1,03,400	
Income from Patient Care Services (Home Care)		1,90,850	-
Income from Registration Fees	1 1	2,19,800	23
Income from RO Plant Accessories		1,95,720	. 5
Income from Uroflowmetery	1 1	45,854	
Income from USG		10,000	
Income from X-ray	1 1	2,31,800	**
Income from Consultation Fees		2,00,940	
Sales Of Consumable		11,82,954	*
Sales Of Diet Sales		3,03,650	
Sales Of Hemodialysis Machine	1 1	14,67,200	
Sales Of Medicine & Medical equipments		1,07,95,129	60,53,879
Total		3,42,43,739	1,82,47,069
Other Income	2.02		025022
Income From Interest on Income Tax Refund			12,600
Income From Fixed Deposit Interest		10,400	78,490
Discount Received	1 1	26,001	
Miscellaneous Receipt		3,197	
Total		39,598	91,090
Purchases(Cost of Material Consumed)	2.03	100000000000000000000000000000000000000	
Purchases of Dialysis Materials	1 1	38,30,082	1,24,53,326
Purchases of Re-Agent Materials		7,41,731	
Purchases of Medicine	DX.	1,03,67,864	
Purchases of Hemodialysis Machine	_	13,44,700	
Total -	679000	1,62,84,377	1,24,53,326
Changes in Stock	2.04		4 07 470
Opening Stock	1 1	2,51,970	1,85,150
Closing Stock	- 1	17,05,862	2,51,970
Total		(14,53,892)	(66,820
Employee Benefits Expenses	2.05	22.42.22	44 00 000
Salary & Bonus		25,49,774	11,77,200
Staff- Incentive		1,19,500	75,700
Staff- Welfare	_	65,725	***********
Total		27,34,999	12,52,900

Nephro Care India Pvt. Ltd.

Nephro Care India Pvt. Ltd.

Pritain Sengupter

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050

Notes forming part of the statement of Profit and loss for the year ended 31st March 2022

PARTICULARS		For the year ended	For the year ended
	Note	31st March, 2022	31st March, 2021
		Amount In ₹	Amount In ₹
Financial Cost	2.06		CONTRACT
Bank Charges		18,579	10,894
Interest on Ioan	1 1	1,47,021	2,25,071
Total]	1,65,600	* 2,35,965
The second secon	4		
Other Expenses	2.07		
Audit Fees		40,000	30,000
Attendant Charges & Word boy			2,72,300
Advertisment Expenses	1 1	66,693	
Bio-Medical Waste Cleaning Charges		39,590	
Brokerage Paid	1 1	11,950	7/2
Canteen Expenses	1 1	1,87,495	2,01,030
Clearing Expenses		8,380	1,84,500
Convyence		1,28,556	**
Consultancy Charges		2,51,788	
Commission Expenses	1 1	2000	99,735
Delivery Expenses	1 1	3,500	
Dialysis Machine Hire Charges	1 1	12,60,000	10,08,000
Dialysis Patients Food		42,940	
EDC-Rental		8,083	10,030
Electricity Charges	1 1	2,72,785	6,00,000
Employer Contributo to PF	1: 1	90,384	// V.07/385377 \$1
Employer Contributo to PF -Admin & EDLI Charges		6,000	-
Electricity Connection & Installation Charges		4,07,912	
[M. [전통] 이 경우 (2017) (A. 2017)		33,580	
Fright Expenses	1 1	6,68,628	3
General Expenses		45,285	
Genset Charge	1 1		1,38,953
House Keeping Expenses	1 1	5,19,108	1,00,700
Interest on late payment of Ptax	1 1	680	
Inaugeration expenses	1 1	2,22,738	
Loading & Unloding Expenses		100	<u> </u>
Material shiffting Charge	1 1	5,000	4 14 900
Office Running Expenses	1 1	58,580	1,41,783
OT Materials Purchases		93,545	*
Doctors Consultancy	1 1	24,000	
Outsource Lab and other test Charge	1 1	56,29,206	
Permission Fees for land use	1 1	7,13,208	
Postage & Courier	1 1	15,540	
Printing & Stationery	1 1	86,148	
Printing	1 1	1,40,230	, 2,
P TAX-Company		2,500	2,50
Rent		24,11,920	8
Room Rent		1,33,000	
Repair & Maintenance		7,74,456	91,433
ROC - filling Govt Fees		82,600	
Socurity Service Charge		26,322	<u></u>
Software Maintenance Charge	1 1	77,880	1.0
ROSE - Com - March 191 - SW / 1	1 1	2,500	
Subscription & Donation		11,61,100	
Technician Charge for Dialysis		45,687	
Telephone & Interenet Charge	9	2,150	
Trade Licence Fees		30,000	1 0
Viedeos & Photography Charge		27777670	
Washing Expneses		61,503	25.04
Professional Fees (Tax consultance)			25,000
OT Assistant Expenses		7,500	115

Pratim lengrater Director

Pritam Sugapta.

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Statement of Profit and loss for the year End 31st March 2022

PARTICULARS	Note	For the year ended 31st March, 2022 Amount In ₹	For the year ended 31st March, 2021 Amount In
1. Revenue From Operations			
Revenue from operations(net)	2.01	3,42,43,739	* 1,82,47,069
Total		3,42,43,739	1,82,47,069
2. Other Income	2.02	39,598	91,090
3. Total Revenue(1+2)		3,42,83,337	1,83,38,159
4. Expenses:	779-54	Pennananan	
Cost of materials consumed	2.03	1,62,84,377	1,24,53,326
Increase/(Decrease) in Stock	2.04	(14,53,892)	(66,820)
Employee Benefits expenses	2.05	27,34,999	12,52,900
Finance costs	2.06	1,65,600	2,35,965
Depreciation	1.08	11,14,266	1,29,849
Other expenses	2.07	1,59,00,750 3,47,46,100	28,05,264 1,68,10,484
Total Expenses		3747,440,100	1,00,10,101
5. Profit before Exception and extraordinary items and tax(3,-4)		(4,62,763)	15,27,675
6. Exceptional items		-	
7. Profit before Exception items and tax(5-6)		(4,62,763)	15,27,675
8.Extraordinary items		-	2
9. Profit before Tax (7-8)		(4,62,763)	15,27,675
10. Tax Expenses:			
(1) Current tax	1.07	• •	3,65,776
(2) Deferred tax	1.05	50,47,282	(1,89,639)
11. Profit for the period from continuing operatios(9-10)		(55,10,045)	13,51,538
12.A Profit/(loss) from discontinuing Operation			
Profit Transferred to Balance Sheet		(55,10,045)	13,51,538
BASIC EPS		-11.02	135.15
DIALUTED EPS		-11.02	135.15

NOTES TO ACCOUNTS

Schedules referred to above and notes attached there to form an integral part of Profit & Lose Statement This is the Profit & Loss Statement referred to in our Report of even date.

FOR ABRS & ASSOCIATES Firm Registration No. - 017964C CHARTERED ACCOUNTANTS

(CA. Sampa Dey)

Partner

Membership No.: 069814

FRN.-017964C Date: 30/09/2022 Place: Kolkata

FOR & ON BEHALF OF THE BOARD

FOR NEPHRO CARE INDIA PVT LTD

Nophro Care India Pro Platim Sengupta

Director

Nephro Care India Pvt. Ltd. Dr. Pritam Sengupta

Director Pritain Sepportobiosons Director

UDIN-

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Balance Sheet as at 31st March 2022

PARTICULARS		Note	For the year ended 31st March, 2022 Amount In ₹	For the year ended 31st March, 2021 Amount In ₹
EOUITY AND LIABILITIES				141
1) Shareholders' Funds :-	*			
(a) Share Capital		1.01	50,00,000	1,00,000
(b) Reserves and Surplus		1.02	(34,38,455)	20,71,590
(2) Share Application Money pending allotment			-	
(3) Non-Current Liabilities				
Long term Borrowings		1.03	2,55,50,144	69,26,506
4) Current Liabilities :-				
(a)Short term Borrowings			5	
(b) Trade Payable		1.04	1,40,65,711	30,77,634
(c) Other Current Liabilities		1.05	14,32,211	4,71,238
(d) Deferred Tax Liabilities (Net)		1.06	48,59,114	(1,88,168)
(e) Short Term Provisions		1.07		3,65,776
Total		4	4,74,68,725	1,28,24,576
(i. 1989)				
ASSETS				
1) Non-Current Assets :-			1505405/85000	7829887000
(a) Fixed Assets : Tangible Assets		1.08	3,29,22,521	51,12,478
(b) Non -Current Investment		1.09	17,11,423	24,00,000
(c) Deferred tax assets(Net)				
(d) Long term loans and advances				
2) Current Assets :-				
(a) Inventorise	(4	2.04	17,05,862	2,51,970
(b) Trade receivables		1.5-47.00	19,27,269	
(c) Cash and bank balances		1.10	60,89,950	48,22,206
(d) Short term loans and advances		1.11	8,99,383	5,887
(f) Other current assets	AL.	1.12	22,12,316	2,32,036
Total			4,74,68,725	1,28,24,577

NOTES TO ACCOUNTS

Schedules referred to shove and notes attached there to form an integral part of Balance Sheet This is the Balance Sheet referred to in our Report of even date.

FOR ABRS & ASSOCIATES

Firm Registration No. - 017964C

CHARTERED ACCOUNTANTS

(CA. Sampa Dey)

Partner

Membership No.: 069814

FRN-017964C Date: 30/09/2022 Place: Kolkata



FOR & ON BEHALF OF THE BOARD FOR NEPHRO CARE INDIA PVT LTD

Nephro Care India Rivinshipupta

Nephro Care India Pvt. Lift Pritam Sengupta Director

Phitam Singuptu. Director

DIN-06795012

UDIN-

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Note forming Part of the Balance Sheet as at 31st March 2022

PARTICULARS		For the year ended 31st March, 2022 Amount In ₹	For the year ended 31st March, 2021 Amount In
1.02 Reseves and Surplus			
Surplus			
Opening Balance		20,71,590	7,20,053
Add: Net Profit transferred from Statement of		(55,10,045)	13,51,537
Profit and loss			
	Total	(34,38,455)	20,71,590

NEPHRO CARE INDIA PRIVATE LIMITED

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Notes forming part of the Balance sheet as at 31st March 2022

1.03 Long Term Borrowings		
Secured:		
HDB Finance Service	11,65,516	18,33,589
Unsecured	5-0.000,000	
Loan from Directors(Pratim Sengupta-U/L)	2,43,84,628	50,92,917
552	2,55,50,144	69,26,506
1.04 Trade Payables:	8 1	
Sundry Creditors For Supplies & others	*	22222
IBM	4,17,823	6,36,655
Vikas Medical Devic	21,86,200	1,24,740
Zenith Aquatech	1,62,716	91,568
Arivation Helthcare	6,28,216	3,74,932
Other	1,06,70,756	18,49,739
	1,40,65,711	30,77,634
1.05 Other Current Liabilities		
Professioanl Tax		2,500
TDS Payable	6,91,553	
P.tax Payable (Employee)	8,260	7,640
Salary Payable	3,75,874	1,24,500
P.F Payable (Employee)	14,460	21,186
P.F Payable (Employer)	15,064	21,186
Administrative Charges &DLI	1,000	2,385
Audit Fees Payable	40,000	30,000
Professioanal fees		32,341
	2,86,000	
Outside Lab Test Expenses Payable	2,00,000	665
GST payable OCIATES		2,28,844
Other Expenses Payable	14,32,211	4,71,247
(a) 25 \ [8]		
1.06 Deffered Tax Liabilities:	100000000	9507000
Opening Balance	(1,88,168)	1,471
Adjusted during the year	50,47,282	(1,89,639)
Closing Balance	48,59,114	(1,88,168
1.07 Short Term Provision		
Income Tax Provision		3,65,776
		3,65,776
Nephro Care India Pvt. Ltd.		

Pritam Senguph.

1.08 Investment	1 1	
Fixed Deposit	17,11,423	24,00,000
	17,11,423	24,00,000
1.10 Fees Receivable		
Fees Receivable	19,27,269	
	19,27,269	-
1.11 Cash and cash Equivalents		
Cash in hand	12,92,382	49,119
(As Certified by the Management)	00000000	1 540 84405
Balance with scheduled Bank in current Account		
HDFC Bank, A/C no 50200009559026	24,97,583	40.18,906
HDFC Bank, A/C no 5020047894763	9.83,259	3,49,327
HDFC Bank, A/C no 5020054691630	60,971	50,971
HDFC Bank, A/C no 5020054691643	50,971	50,941
HDFC Bank, A/C no 5020054691745	50.971	50,941
HDFC Bank, A/C no 5020054691886	4.52,872	50,941
HDFC Bank, A/C no 5020054691923	50,971	50,971
HDFC Bank, A/C no 5020054698042	6,49,971	1,50,000
	60,89,950	48,22,117
1.12 Short Term Loans & Advances	-	
TDS	82,439	5,887
TCS	1,493	S.
Advance Tax (for the FY 2021-2022)	2,00,000	-
Advance to Employee	21,500	
GST input	5,93,951	
- 67	8,99,383	5,887
1.13 Other Current Assets		
Interest Accured on Fixed Deposit	59,827	1,80,347
Investment -HDFC SLIC	51,689	51,689
Security Deposit	21,00,800	-
	22,12,316	2,32,036

Nephro Care India Pvt. Ltd.

Director

Nephro Care India Pvt. Ltd.

Pritam Singupta.



FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Note forming Part of the Balance Sheet as at 31st March 2022

PARTICULARS		For the year ended 31st March, 2022 Amount In	For the year ended 31st March, 2021 Amount In ₹
1.02 Resrves and Surplus Surplus Opening Balance Add: Net Profit transferred from Statement of		20,71,590 (55,10,045)	- 7,20,053 13,51,537
Profit and loss	Total	(34,39,455)	20,71,590

NEPHRO CARE INDIA PRIVATE LIMITED

FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050 Notes forming part of the Balance sheet as at 31st March 2022

Notes forming part of the Balance she	ge as at 31st March 2022	
1.03 Long Term Borrowings		
Secured: HDB Finance Service	11,65,516	18,33,589
Unsecured	49000 1010	
Loan from Directors(Pratim Sengupta-U/L)	2,43,84,628	50,92,917
	2,55,50,144	69,26,506
1.04 Trade Payables:		- 1
Sundry Creditors For Supplies & others		X 04 455
1BM	*4,17,823	6,36,655
Vikas Medical Devic	21,86,200	1,24,740
Zenith Aquatech	1,62,716	91,568 3,74,932
Arivation Helthcare	6,28,216	18,49,739
Other	1,06,70,756	the second second second second second
35001755-2	1,40,65,711	30,77,634
1.05 Other Current Liabilities		2,500
Professioani Tax	6,91,553	+
TDS Payable	8,260	7,640
P.tax Payable (Employee)	3,75,874	1,24,500
Salary Payable	14,460	21,186
P.F Payable (Employee)	15,064	21,186
P.F Payable (Employer)	1,000	2,385
Administrative Charges &DLI	40,000	30,000
Audit Fees Payable	-	32,341
Professioanal fees	2,86,000	
Outside Lab Test Expenses Payable	2,00,000	665
GST payable		2,28,844
Other Expenses Payable	14,32,211	4,71,247
(2) (E)		
1.06 Deffered Tax Liabilities:	(1,88,168)	1,471
	50,47,282	(1,89,639)
Adjusted during the year	48,59,114	(1,88,168)
Closing Balance		
1.07 Short Term Provision		3,65,776
Income Tax Provision		3,65,776

Nephro Care India Pvt. Ltd.

Nephro Care India Pvt. Ltd.

Rikum Singuph .
Director

1.08 Investment	1 1	
Fixed Deposit	17,11,423	24,00,000
Wester State	17,11,423	24,00,000
1.10 Fees Receivable		
Fees Receivable	19,27,269	120
	19,27,269	-
1.11 Cash and cash Equivalents		
Cash in hand	12,92,382	+ 49,119
(As Certified by the Management)		400,000
Balance with scheduled Bank in current Account		
HDFC Bank, A/C no 50200009559026	24,97,583	40,18,906
HDFC Bank, A/C no 5020047894763	9,83,259	3,49,327
HDFC Bank, A/C no 5020054691630	60,971	50,971
HDFC Bank, A/C no 5020054691643	50,971	50,941
HDFC Bank, A/C no 5020054691745	50,971	50,941
HDFC Bank, A/C no 5020054691886	4,52,872	50,941
HDFC Bank, A/C no 5020054691923	50,971	50,971
HDFC Bank, A/C no 5020054698042	6,49,971	1,50,000
Control of the self-control of the self-control of the control of	60,89,950	48,22,117
1.12 Short Term Loans & Advances		
TDS	. 82,439	5,887
TCS	1,493	
Advance Tax (for the FY 2021-2022)	2,00,000	347
Advance to Employee	21,500	
GST input	5,93,951	
	8,99,383	5,887
1.13 Other Current Assets	· ·	
Interest Accured on Fixed Deposit	59,827	1,80,347
Investment -HDFC SLIC	51,689	51,689
Security Deposit	21,00,800	
	22,12,316	2,32,036

Nephro Care India Pyt. Ltd.

Pratin Supple

Director

Nephro Care India Pvt. Ltd.

Pritum Segupta.



NEPHRO CARE INDIA PRIVATE LIMITED FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALL 25/10, HARRY KRISHTO SETT LANE ,KOLKATA-700051

NOTE - 1.08 FIXED ASSETS SCHEDULE

		GROSS BLOCK					DEPRECIA	ATION		NET BL	оск
Name of the Assets	Pate of Tax	Cost as an 01.04,2021	Addition during the year	Seles/ Deductions during the year	Cost as on 31,03,2022	Depreciation as on 01,04,2021	Far the Year	Adjustments on Sales/ Deductions	Total as an 31,03,2022	As on 31,03,2022	As on 31.03.2021
Nephrology Equipment	0.00%	22,53,153			22,53,153	35	- 3	-	. d	22,53,153	22,63,163
Computer	63.16%	21,063	4,55,844		4,76,907	19,579	53,731.37		73,310	4,03,597	1,454
Renovation Chembers	0.00%	22,78,575	1,44,54,580	14	1,67,33,085			- 12	- 6	1,67,33,085	22,78,575
Furniture & Fixture	25.89%	1,26,947	62,300		1,89,247	32,867	27,937,31		50,804	1,28,443	94,050
Plant & Equipments	16.10%	5,76,909	1,38,54,206	3	1,44,31,115	92,724	10,22,717.49		11,15,441	1,33,15,674	4,84,185
Server	63.16%	2,714	*		2,714	1,714	631.60		2,346	368	1,000
Electricity Equipment	18,10%		97,450		97,450	1	9,247.96		9,248	88,202	- A (2-
Total		52,59,361	2,89,24,310	-	3,41,03,675	1,46,884	11,14,266		12,61,150	3,29,22,521	51,12,477

CHATES & SEARCH CHAMES

Nephro Care India Pvt. Ltd.

Director

Nephro Care India Pvt. Ltd.

Pritam Singupta Director

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

Note: 1.01 Share Capital

Sr. No	Particulars
1	AUTHORIZED CAPITAL
	100,000 Equity Shares of Rs. 10/- each.
	500,000 Equity Shares of Rs. 10/- each.
2	ISSUED, SUBSCRIBED & PAID UP CAPITAL
	To the Subscribers of the Memorandum
	100,000 Equity Shares of Rs. 10/- each, Fully Paid up
	500,000 Equity Shares of Rs. 10/- each, Fully Paid up
	Total in (Rs.)

larch 2022 (Rs.)
50,00,000
50,00,000
50,00,000
50,00,000

7.	31st March 2021(Rs.)
*	10,00,000
-	10,00,000
	1,00,000
	1,00,000

A Reconciliation of the shares outstanding at the beginning and at the end of the reporting period Equity Shares 31st March 2022

At the beginning of the reporting period Issued during the period Outstanding at the end of the reporting period

31st March 2022			31st March 2021			
No. of Shares		Amount (Rs.)	No. of Shares	Amount (Rs.)		
	10,000	1,00,000	10,000	1,00,000		
	4,90,000	49,00,000	5.4			
	5,00,000	50,00,000	10,000	1,00,000		
-		The same of the sa				

B Terms/rights attached to equity shares

The company has only one class of equity shares having a par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per

C Details of shareholders holding less than 5% shares in the company

	31st Mar	31st March 2021		
Name of the Shareholders	No. of Shares	% Holding	, No. of Shares	% Holding
Dr. Pretim Sengupte	498000	99.6%	8000	80%
Dr. Pritam Sengupta	2000	0.4%	2000	20%

Nephro Care India Pvt. Ltd.

Director

Nephro Care India Pvt. Ltd.

Pritam Sengupta.



NEPHRO CARE INDIA PRIVATE LIMITED FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE ,KOLKATA-700050

SCHEDULE FORMING PART OF BALANCE SHEET AS AT 31/03/2022

- mess				Addition		The owner was the	Total	Depreciation	Written Down
SNO		Rate of Deprn.	W.D.V. AS ON 01-04-2021	More than 180 days	Less than 180 days	Sale/ Adjustment	As on 31.03.2022	Allowable	Value as on 31.03.2022
	Tangible Asset Furn & Fittings - 10% Block Furniture & Fixture	10%	1,14,252	2,600	59,700		1,76,552	14,670	1,61,882
	Plant & Equipments - 15% Block Plant & Equipments Electricity Equipment	15% 15%	4,90,373	44,72,398 90,500	93,81,810 6,950		1,43,44,581 97,450	14,48,051 14,096	1,28,96,530 83,354
1	Computer - 40% Block Computer Server	40% 40%	3,049 2,714		4,55,844	-	4,58,893 2,714	92,388 1,086	3,66,505 1,628
VALUE OF	Total		6,10,388	45,65,498	99,04,304	1 Table 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	1,50,80,190	15,70,292	1,35,09,898

Nephro Care India Pvt. Ltd.

Nephro Care India Pvt. Ltd.

Pritam Tengupta.



ABRS & ASSOCIATES

Chartered Accountants

AUDITOR'S REPORT

The Members,

NEPHRO CARE INDIA PRIVATE LIMITED FLAT NO. GC, GROUND FLOOR, BLOCK B, AMRAPALI, 29/10, HAREY KRISHTO SETT LANE, KOLKATA, WB 700050 IN

Report on the Financial Statements

We have audited the accompanying financial statements of NEPHRO CARE INDIA PRIVATE LIMITED which comprise the Balance Sheet as at 31st March 2022, & the Statement of Profit and Loss and for the year ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of these financial statements that give a true and fair view of the financial position & financial performance of the Company in accordance with the Accounting Standards referred to in section 133 of the Companies Act, 2013. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matters

We draw attention to the following matters in the notes to the financial statements:

(a) Balances under Current Liabilities and Current Assets have not been confirmed. Consequential impact on confirmation/reconciliation of such balance, if any is not ascertainable.



ABRS & ASSOCIATES

Chartered Accountants

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- in the case of the balance sheet, of the state of affairs of the Company as at 31st March 2022;
- ii. in the case of the statement of profit and loss, of the profit for the year ended on that date;

Report on Other Legal and Regulatory Requirements

- 1. As required by section 143 of the Act, we report that:
 - a. we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. in our opinion, the Balance Sheet & Statement of Profit and Loss comply with the Accounting Standards referred to in Section 133 of the Companies Act, 2013; and
 - e. on the basis of written representations received from the directors as on 31st March 2022, and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2022, from being appointed as a director in terms of sub-section (2) of Section 164 of the Companies Act, 2013.

UDIN- 22069814BBPOAU6133

ASSOCIA AND ASSOCI

Place: Kolkata Dated: 30/09/2022 FOR ABRS & ASSOCIATES CHARTERED ACCOUNTANTS

CA SAMPA DEY

PARTNER

MEMBERSHIP NO: 069814

FRN: 017964C

BOARD'S REPORT

To The Members

Your Directors have pleasure in presenting the Annual Report together with the Audited Statement of Accounts of your Company for the financial year ended March 31st. 2022.

FINANCIAL HIGHLIGHTS

(Amount inRs)

Particulars	Year ended 31" March 2022	Year ended 31s March 2021	
Revenue from operation (gross)	3,42,43,739	1,82,47,069	
Other Income	39,598	91,090	
Total Expenses	3,47,46,100	1,68,10,484	
Profit/(Loss) before taxation	(4,62,763)	15,27,675	
Less: Tax Expense (Current tax)	NIL	3.65.776	
Less Tax Expense (Deterred Tex)	50,47,287	(1,89.639)	
Profit/(Loss) after tax	(55,10,045)	13,51,538	

DEVIDEND

No Dividend was declared for the current financial year.

TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCTION AND PROTECTION FUND

The provisions of Section 125(2) of the Companies Act, 2013 do not apply as there was no dividend declared and paid last year.

TRANSFER TO RESERVES

Profit after Tax for the year ending as 31st March 2022 is transferred to the Reserves.

STATE OF THE COMPANY'S AFFAIRS AND FUTURE OUTLOOK

The Company is engaged in the business of Healthcare services ensuring medical support to the persons suffering from nephrology disorder and by giving them indoor and outdoor medical treatment facility and Medicine sales also. There has been no change in the business of the Company during the financial year ended 31" March, 2022.

Nephro Care India Pvt. Ltd.

Nephro Care India Pvt/Ltd.

Office address


Nephrocare India Pvt. Ltd. T& JC Block Ln, JC Block, 5th & 6th Floor

Directs intered address

Nephrocare India Put Ltd. Topapan, 298/1 Harey Kishna Sett Lane

www.nephrotaremaia.com o unDirectofnicarenda com @ 033 4009 8676

SHOT ON REDMI 7 KONGIO 700050 AI DUAL CAMERA



MATERIAL CHANGES AND COMMITMENTS

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statement relates and the date of this report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS & OUTGO:

A. Conservation of Energy, Technology Absorption

The particulars as required under the provisions of Section 134(3)(m) of the Companies Act, 2013 in respect of conservation of energy and technology absorption have not been furnished considering the nature of activities undertaken by the company during the year under review.

B. Foreign Exchange Earnings and Outgo

Earnings	NIL.	
Outgo	NIL	

RISK MANAGEMENT

The Company does not have any Risk Management Policy as the elements of risk threatening the Company's existence are very minimal.

DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

The Company has not developed and implemented any Corporate Social Responsibility initiatives as the said provisions are not applicable.

LOANS, GUARANTEES AND INVESTMENTS

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act. 2013 are given in the notes to the Financial Statements.

RELATED PARTY TRANSACTIONS

The details of the Related Party Transactions are stated in the Notes to Accounts for the year ended 31st March 2022.

EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS

There are no qualifications, reservations or adverse remarks made by the Auditors in their report. The provisions relating to submission of Secretarial Audit Report Is not applicable to the Company.

COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

The provisions of Section 178(1) relating to constitution of Nomination and Remuneration Committee are not applicable to the Company.

Nephro Care India Pvt. Ltd.

Nephro Care India Pvt. Ltd.

Pritam Sengyota.

Registered address

@ 033 4009 8676

www.nephrocareindia.com o supportionephrocarendia.com

Office add XTRACT OF ANNUAL RETURN Nephroare India Pv 11to In, JC Block, 5th & 6th Floor

ector my bidharmagás, Köllytá, 70,3126 (= 1 -

Nephrocare India Pvt. Ltd. Tapaban, 29B/1 Harey Krishno Sett Lane Kolkata 700050



The extract of Annual Return in form no. MGT-9 as required under Section 92 of the Companies Act. 2013 for the financial year ending 31th March, 2022 is annexed hereto as Annexure A and forms part of this report.

MEETINGS OF THE BOARD OF DIRECTORS

During the financial year ended 31st March, 2022, 7 (Seven) Meetings of the Board of Directors of the Company were held.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

- (a) The preparation of the annual accounts for the year ended 31° March, 2022, the Company has followed the applicable accounting standards and there are no material departures from the same.
- (b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31° March, 2022and of the profit and loss of the Company for that period:
- (c) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities:
- (d) the Directors have prepared the annual accounts on a 'going concern' basis;
- (e) the Company being unlisted, sub-clause (e) of section 134(3) of the Companies Act, 2013 pertaining to laying down internal financial controls is not applicable to the Company;
- (f) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANIES

The Company does not have any Subsidiary, Joint Venture or an Associate Company.

DEPOSITS

The Company has not accepted any deposits during the year under review.

DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP)

In view of the applicable provisions of the Companies Act, 2013, the Company is not mandatorily required to appoint any whole time KMPs.

DECLARATION OF INDEPENDENT DIRECTORS

The provisions of Section 149 for appointment of Independent Directors do not apply to the company.

ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

The Company has in place adequate internal financial controls with reference to financial statements. During the year under review, such controls were tested and no reportable material weakness in the resign of Care india PVI. Ltd.

Nephro Care India PVI. Ltd.

Office address

hr e Inca 11 tro N R E D

(lock Ln, JC Block, 5th & 6th Floor
Sector In, oidhantachi, JC kala 2001 6th

Registered address Printern Congress
Nephrocare India Pvt. Uta. Director
Tapaban. 298/1 Harey Krishno Sett Lane
Kolkata 700050

e www.uebuccare.pirector

o 33 4009 8676



STATUTORY AUDITORS

M/I M DATTA & ASSOCIATES. Chartered Accountants, the Statutory Auditors of the Company has expressed their willingness to get reappointed in the ensuing Annual General Meeting. The Board recommends their re-appointment for the financial year 2022-23.

DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 and 7 of the Companies (Meetings of the Board and its Powers) Rules. 2013 is not applicable to the Company.

SHARES

During the year under review, the company has undertaken following transactions:

Increase in Share Capital	Huy Back of Securities	Swent Equity	Bonus Shares	Employees Stock Option Plan
Authorized capital increase from 10 Lakh to 50 Lakh and Paid up capital increase from 1 Lakh to 50 Lakh	Nil	Nit	Nil	Nit

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS

No order, whether significant and/or material has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company is committed to provide a safe and conducive work environment to its employees.

ACKNOWLEDGMENT

Your Directors would like to express their sincere appreciation for the assistance and cooperation received from the financial institutions, banks, Government authorities, customers, vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the Company's executives, staff and workers.

For and on behalf of the Board of Directors NEPHRO CARE INDIA PRIVATE LIMITED

Nephro Care India Pvt. Ltd.

PRATIM SENGUP Director

DIN: 03501703

Nephro Care India Pvt. Ltd.

PRITAM SENGUPTA Sengrapha

DIN: 06795012

Date:30/09/2022

Place: Kolkata SHOTON RE

Nephrocare India Nrt Ltd.AL CAMER. 18 JC Block Ln, JC Block, 5th & 6th Floor Registered address

Nephrocare India Pvt. Ltd. Tapaban, 298/T Harey Krishno Sett Lane Kalkata 700050 www.nephrocareindia.com

e support@nephrocareindia.com

e 033 4009 8676



ANNEXURE - A

EXTRACT OF THE ANNUAL RETURN IN FORM MGT-9:

Pursuant to section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration)

Related Party Transactions:

Particulars of contracts or arrangements with related parties referred to in sub-section (I) of section 188 in the form

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business.

Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014;

- 1. Details of contracts or arrangements or transactions not at arm's length basis: Nil
- 2. Details of material contracts or arrangement or transactions at arm's length basis:

Name(s) of the related party and nature of relationship	Nature of contracts/arrangement/transactions	Duration of the contracts / arrangements/tr ansactions	Salient terms of the contracts or arrangements or transactions including the value, if any:	Date(s) of approval by the Board, if any:	Amount paid as advances, if any:
Loan from Directors(PratimSengup in)	Long Term Borrowings	NA	NA:	.NA	2,43,84,628/-

For and on behalf of the Board of Directors
Nephro Care India Private LIMITED

PRATIM SENGE

Director

DIN: 03501703

Date: 30/09/2022 Place: Kolkata

Nephro Care India Pvt. Ltd.

PRITAM SENGUPTA Pritam Sengupte -

DIN: 06795012

Office address

Jephrocare India Pvt Ltd. LI, JC Block, Sun & Gair Floor 8, IC F adh riagas, Schalla 700 165

Registered address

Mephrocare India Pvt. Ltd. Tapaban, 298/1 Harey Krishno Sett Lane Kokata 700050

www.nephrocareindia.com

o support@nephrocareindia.com

0 033 4009 8676